Factors | Group A (EVD less than 7 days) Mean = 5.44 ± 1.78 days | Group B (EVD more than 7 days) Mean = 13.72 ± 5.81 | Overall Mean = 10.23 ± 6.14 | P-value |
Number of Patients (n) | 16 | 22 | 38 |
|
|
|
|
|
|
Age (In Months) Mean ± SD |
54.19 ± 24.52 |
66.73 ± 33.57 |
61.45 ± 30.37 |
0.21 |
Sex |
|
|
|
|
Male, n (%) | 10 (62.50%) | 12 (54.55%) | 22 (57.89%) | 0.62 |
Female, n (%) | 6 (37.50%) | 10 (45.45%) | 16 (42.11%) |
|
Duration of Symptoms |
|
|
|
|
Less than 1 month, n (%) | 10 (62.50%) | 14 (63.64%) | 24 (63.16%) | 0.94 |
More than 1 month, n (%) | 6 (37.50%) | 8 (36.36%) | 14 (36.84%) |
|
Clinical Features |
|
|
|
|
Signs of raised ICP only, n (%) | 13 (81.25%) | 17 (77.27%) | 30 (78.95%) | 0.81 |
Signs of raised ICP with cranial nerve deficits, n (%) | 2 (12.50%) | 2 (9.09%) | 4 (10.53%) |
|
Signs of raised ICP with head enlargement or delayed milestones, n (%) | 1 (6.25%) | 2 (9.09%) | 3 (7.89%) |
|
Signs of raised ICP with loss of consciousness, n (%) | 0 (0.00%) | 1 (4.55%) | 1 (2.63%) |
|
Duration of MRI (In Days) Mean ± SD |
3.25 ± 1.69 |
4.41 ± 1.79 |
3.92 ± 1.82 |
0.04 |
Location of the Tumour |
|
|
|
|
Midline, n (%) | 13 (81.25%) | 18 (81.82%) | 31 (81.58%) | 0.96 |
Lateral, n (%) | 3 (18.75%) | 4 (18.18%) | 7 (18.42%) |
|
CSF Seeding |
|
|
|
|
No, n (%) | 11 (68.75%) | 18 (81.82%) | 29 (76.32%) | 0.80 |
Yes, n (%) | 5 (31.25%) | 4 (18.18%) | 9 (23.68%) |
|
Diagnosis |
|
|
|
|
Medulloblastoma, n (%) | 8 (50.00%) | 14 (63.64%) | 22 (57.89%) | 0.65 |
Pilocytic astrocytoma, n (%) | 3 (18.75%) | 5 (22.73%) | 8 (21.05%) |
|
Anaplastic ependymoma, n (%) | 3 (18.75%) | 2 (9.09%) | 5 (13.16%) |
|
Ewing’s sarcoma, n (%) | 1 (6.25%) | 0 (0.00%) | 1 (2.63%) |
|
Cavernous haemangioma, n (%) | 1 (6.25%) | 1 (4.55%) | 2 (5.26%) |
|
Surgery |
|
|
|
|
Gross total, n (%) | 13 (81.25%) | 18 (81.82%) | 31 (81.58%) | 0.96 |
Subtotal, n (%) | 3 (18.75%) | 4 (18.18%) | 7 (18.42%) |
|
CSF Leak |
|
|
|
|
No, n (%) | 13 (81.25%) | 20 (90.91%) | 33 (86.84%) | 0.63 |